56 related articles for article (PubMed ID: 12667665)
21. The role of chemokines in Guillain-Barré syndrome.
Chiang S; Ubogu EE
Muscle Nerve; 2013 Sep; 48(3):320-30. PubMed ID: 23447114
[TBL] [Abstract][Full Text] [Related]
22. Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models.
Hebron ML; Algarzae NK; Lonskaya I; Moussa C
Exp Neurol; 2014 Jan; 251():127-38. PubMed ID: 23333589
[TBL] [Abstract][Full Text] [Related]
23. Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases.
Desforges NM; Hebron ML; Algarzae NK; Lonskaya I; Moussa CE
Int J Alzheimers Dis; 2012; 2012():345472. PubMed ID: 22919540
[TBL] [Abstract][Full Text] [Related]
24. Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis.
Mills JH; Alabanza LM; Mahamed DA; Bynoe MS
J Neuroinflammation; 2012 Aug; 9():193. PubMed ID: 22883932
[TBL] [Abstract][Full Text] [Related]
25. Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.
Donohue MM; Cain K; Zierath D; Shibata D; Tanzi PM; Becker KJ
Stroke; 2012 Sep; 43(9):2300-6. PubMed ID: 22798324
[TBL] [Abstract][Full Text] [Related]
26. G protein-coupled receptors as therapeutic targets for multiple sclerosis.
Du C; Xie X
Cell Res; 2012 Jul; 22(7):1108-28. PubMed ID: 22664908
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.
Chalbot S; Zetterberg H; Blennow K; Fladby T; Grundke-Iqbal I; Iqbal K
Neurosci Lett; 2010 Jul; 478(3):179-83. PubMed ID: 20470866
[TBL] [Abstract][Full Text] [Related]
28. Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death.
Lauro C; Cipriani R; Catalano M; Trettel F; Chece G; Brusadin V; Antonilli L; van Rooijen N; Eusebi F; Fredholm BB; Limatola C
Neuropsychopharmacology; 2010 Jun; 35(7):1550-9. PubMed ID: 20200508
[TBL] [Abstract][Full Text] [Related]
29. CNS immune responses following experimental stroke.
Zierath D; Thullbery M; Hadwin J; Gee JM; Savos A; Kalil A; Becker KJ
Neurocrit Care; 2010 Apr; 12(2):274-84. PubMed ID: 19714497
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?
Brettschneider J; Petzold A; Süssmuth S; Tumani H
J Neurol; 2009 Jan; 256(1):3-12. PubMed ID: 19267167
[TBL] [Abstract][Full Text] [Related]
31. Fractalkine and TGF-beta1 levels reflect the severity of chronic pancreatitis in humans.
Yasuda M; Ito T; Oono T; Kawabe K; Kaku T; Igarashi H; Nakamura T; Takayanagi R
World J Gastroenterol; 2008 Nov; 14(42):6488-95. PubMed ID: 19030200
[TBL] [Abstract][Full Text] [Related]
32. Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke.
Gee JM; Kalil A; Thullbery M; Becker KJ
Stroke; 2008 May; 39(5):1575-82. PubMed ID: 18323496
[TBL] [Abstract][Full Text] [Related]
33. The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury.
Rancan M; Bye N; Otto VI; Trentz O; Kossmann T; Frentzel S; Morganti-Kossmann MC
J Cereb Blood Flow Metab; 2004 Oct; 24(10):1110-8. PubMed ID: 15529011
[TBL] [Abstract][Full Text] [Related]
34. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
35. Regulation of CX3CL1/fractalkine expression in endothelial cells.
Imaizumi T; Yoshida H; Satoh K
J Atheroscler Thromb; 2004; 11(1):15-21. PubMed ID: 15067194
[TBL] [Abstract][Full Text] [Related]
36. Fractalkine in rheumatoid arthritis and allied conditions.
Umehara H; Tanaka M; Sawaki T; Jin ZX; Huang CR; Dong L; Kawanami T; Karasawa H; Masaki Y; Fukushima T; Hirose Y; Okazaki T
Mod Rheumatol; 2006; 16(3):124-30. PubMed ID: 16767549
[TBL] [Abstract][Full Text] [Related]
37. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.
Kastenbauer S; Koedel U; Wick M; Kieseier BC; Hartung HP; Pfister HW
J Neuroimmunol; 2003 Apr; 137(1-2):210-7. PubMed ID: 12667665
[TBL] [Abstract][Full Text] [Related]
38. Increased intrathecal release of soluble fractalkine in HIV-infected patients.
Sporer B; Kastenbauer S; Koedel U; Arendt G; Pfister HW
AIDS Res Hum Retroviruses; 2003 Feb; 19(2):111-6. PubMed ID: 12639246
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
